CSIMarket
 


Generex Biotechnology Corp  (GNBT)
Other Ticker:  
 

Generex Biotechnology's Long Term Debt to Equity

GNBT's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


In III Quarter 2021 Generex Biotechnology had stockholder deficit.

Within Major Pharmaceutical Preparations industry Generex Biotechnology Corp achieved the lowest Long Term Debt to Equity in the third quarter 2021. While total ranking remained the same in the third quarter 2021 compared to the previous quarter at no. .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt GNBT´s has?
What is the structure of GNBT´s Equity?


GNBT Long Term Debt to Equity (Apr 30 2021)
III. Quarter
(Jan 31 2021)
II. Quarter
(Oct 31 2020)
I. Quarter
(Jul 31 2020)
IV. Quarter
(Apr 30 2020)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Long Term Debt Change -24.45 % -10.66 % 24.98 % 58.86 % -70.55 %
Long Term Debt to Equity MRQ - - - - -
GNBT's Total Ranking # # # # #
Seq. Equity Change - - - - -
Seq. Long Term Debt Change -13.66 % 0.94 % -6.34 % -7.45 % 2.11 %



Long Term Debt to Equity third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall Market #


Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Financial Statements
Generex Biotechnology's Equity $ -48 Millions Visit GNBT's Balance sheet
Generex Biotechnology's Long Term Debt $ 9 Millions Visit GNBT's Balance sheet
Source of GNBT's Sales Visit GNBT's Sales by Geography


Cumulative Generex Biotechnology's Long Term Debt to Equity

GNBT's Long Term Debt to Equity for the trailling 12 Months

GNBT Long Term Debt to Equity

(Apr 30 2021)
III. Quarter
(Jan 31 2021)
II. Quarter
(Oct 31 2020)
I. Quarter
(Jul 31 2020)
IV. Quarter
(Apr 30 2020)
III. Quarter
Y / Y Equity TTM Growth - - - - -
Y / Y Long Term Debt TTM Growth -24.45 % -10.66 % 24.98 % 58.86 % -70.55 %
Long Term Debt to Equity TTM - - - - 2.13
Total Ranking TTM
Seq. Equity TTM Growth - - - - -
Seq. Long Term Debt TTM Growth -13.66 % 0.94 % -6.34 % -7.45 % 2.11 %


On the trailing twelve months basis During the 12 months period ending III Quarter 2021 company had stockholder deficit.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry GNBT recorded the lowest Long Term Debt to Equity. While total ranking remained unchanged compared to previous 12 month period at no. 0.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt GNBT´s has?
What is the structure of GNBT´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Within the Market #


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0 0 0
 




Companies with similar Long Term Debt to Equity in the quarter ending Apr 30 2021, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityApr 30 2021 MRQ Long Term DebtApr 30 2021 MRQ Equity

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com